Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!

Bibliography

• Egrie J. The cloning and production of recombinant human erythropoietin. Pharmacotherapy 1990;10(Pt 2):3S-8S
   PubMed Web of Science ®Google Scholar
• Browne JK, Cohen AM, Egrie JC, Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 1986;51(Pt 1):693-702
   PubMedGoogle Scholar
• Lin FK, Suggs S, Lin CH, Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985;82(22):7580-4
   PubMed Web of Science ®Google Scholar
• Han F, Wu S, Xue S, Cloning of the human erythropoietin exons and their expression in COS-7 cells. Chin J Biotechnol 1996;12(4):227-33
   PubMedGoogle Scholar
• Maouche L, Tournamille C, Hattab C, Cloning of the gene encoding the human erythropoietin receptor. Blood 1991;78(10):2557-63
   PubMed Web of Science ®Google Scholar
• Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 2000;18(1):13-17
   PubMed Web of Science ®Google Scholar
• Park KD, Mun KC, Chang EJ, Inhibition of erythropoietin activity by cyanate. Scand J Urol Nephrol 2004;38(1):69-72
   PubMed Web of Science ®Google Scholar
• Kitamura T, Tange T, Terasawa T, Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989;140(2):323-34
   PubMed Web of Science ®Google Scholar
• Kitamura T, Tojo A, Kuwaki T, Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989;73(2):375-80
   PubMed Web of Science ®Google Scholar
• Migliaccio AR, Jiang Y, Migliaccio G, Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines. Blood 1993;82(12):3760-9
   PubMed Web of Science ®Google Scholar
• Miura Y, Komatsu N, Suda T. Growth and differentiation of two human megakaryoblastic cell lines; CMK and UT-7. Prog Clin Biol Res 1990;356:259-70
   PubMedGoogle Scholar
• Wojchowski DM, He TC. Signal transduction in the erythropoietin receptor system. Stem Cells 1993;11(5):381-92
   PubMed Web of Science ®Google Scholar
• Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15(3):146-55
   PubMed Web of Science ®Google Scholar
• Sharples EJ, Thiemermann C, Yaqoob MM. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol 2006;6(2):184-9
   PubMed Web of Science ®Google Scholar
• Brines M, Patel NS, Villa P, Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 2008;105(31):10925-30
   PubMed Web of Science ®Google Scholar
• Lee SM, Nguyen TH, Park MH, EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 2004;320(4):1087-95
   PubMed Web of Science ®Google Scholar
• Erslev AJ, Schuster SJ, Caro J. Erythropoietin and its clinical promise. Eur J Haematol 1989;43(5):367-73
   PubMed Web of Science ®Google Scholar
• Graber SE, Krantz SB. Erythropoietin: biology and clinical use. Hematol Oncol Clin North Am 1989;3(3):369-400
   PubMed Web of Science ®Google Scholar
• Liberato NL, Costa A, Barosi G. Erythropoietin: biological aspects and clinical usefulness. Haematologica 1990;75(4):346-62
   PubMed Web of Science ®Google Scholar
• Varet B, Casadevall N, Lacombe C, Nayeaux P. Erythropoietin: physiology and clinical experience. Semin Hematol 1990;27(3 Suppl 3):25-31
   PubMed Web of Science ®Google Scholar
• Koide K, Arai T. Erythropoietin – complications, side effects. Nippon Rinsho 1991;49(Suppl):679-87
   PubMedGoogle Scholar
• Bennett WM. Side effects of erythropoietin therapy. Am J Kidney Dis 1991;18(4 Suppl 1):84-6
   PubMed Web of Science ®Google Scholar
• Samtleben W, Ehmer B, Lutz-Knochenhauer I, Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients. Contrib Nephrol 1991;88:107-16; discussion 17
   PubMedGoogle Scholar
• Gretz N, Lasserre J, Kraft K, Efficacy and side effects of erythropoietin used in the treatment of anemia of uremic rats. Contrib Nephrol 1988;60:236-44
   PubMedGoogle Scholar
• Gretz N, Lasserre JJ, Meisinger E, Potential side-effects of erythropoietin. Lancet 1987;1(8523):46
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G, Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305(5681):239-42
   PubMed Web of Science ®Google Scholar
• Kirkeby A, Torup L, Bochsen L, High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008;99(4):720-8
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101(41):14907-12
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang ZG, Gregg SR, The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 2007;282(44):32462-70
   PubMed Web of Science ®Google Scholar
• Hahn H, Wojnowski L, Miller G, Zimmer A. The patched signaling pathway in tumorigenesis and development: lessons from animal models. J Mol Med 1999;77(6):459-68
   PubMed Web of Science ®Google Scholar
• Park HL, Bai C, Platt KA, Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 2000;127(8):1593-605
   PubMed Web of Science ®Google Scholar
• Scotting PJ, Rex M. Transcription factors in early development of the central nervous system. Neuropathol Appl Neurobiol 1996;22(6):469-81
   PubMed Web of Science ®Google Scholar
• Ming JE, Roessler E, Muenke M. Human developmental disorders and the Sonic hedgehog pathway. Mol Med Today 1998;4(8):343-9
   PubMedGoogle Scholar
• Ueda K, Takano H, Niitsuma Y, Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest 2010;120(6):2016-29
   PubMed Web of Science ®Google Scholar
• Sturm B, Helminger M, Steinkellner H, Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest 2010;40(6):561-5
   PubMed Web of Science ®Google Scholar
• Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood 1980;56(3):344-50
   PubMed Web of Science ®Google Scholar
• Schapira AH. Primary and secondary defects of the mitochondrial respiratory chain. J Inherit Metab Dis 2002;25(3):207-14
   PubMed Web of Science ®Google Scholar
• Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 1991;47(1):22-31
   PubMedGoogle Scholar
• Acquaviva F, Castaldo I, Filla A, Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008;7(3):360-5
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang ZG, Rhodes K, Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151(8):1377-84
   PubMed Web of Science ®Google Scholar
• Minnerup J, Heidrich J, Rogalewski A, The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009;40(9):3113-20
   PubMed Web of Science ®Google Scholar
• Jerndal M, Forsberg K, Sena ES, A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2010;30(5):961-8
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Aust C, Krampe H, Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004;19(3-4):195-206
   PubMed Web of Science ®Google Scholar
• Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22(2):105-19
   PubMed Web of Science ®Google Scholar
• Lapchak PA. Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin Investig Drugs 2008;17(8):1175-86
   PubMed Web of Science ®Google Scholar
• Villa P, van Beek J, Larsen AK, Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 2007;27(3):552-63
   PubMed Web of Science ®Google Scholar
• Lapchak PA, Kirkeby A, Zivin JA, Sager TN. Therapeutic window for nonerythropoietic carbamylated-erythropoietin to improve motor function following multiple infarct ischemic strokes in New Zealand white rabbits. Brain Res 2008;1238:208-14
   PubMed Web of Science ®Google Scholar
• Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res 2010;1(2):96-107
   PubMed Web of Science ®Google Scholar
• Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig 1994;72(6 Suppl):S36-43
   PubMedGoogle Scholar
• Ryffel B. Unanticipated human toxicology of recombinant proteins. Arch Toxicol Suppl 1996;18:333-41
   PubMedGoogle Scholar
• Ehrenreich H, Weissenborn K, Prange H, Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40(12):e647-56
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-98
   PubMed Web of Science ®Google Scholar
• Drueke TB, Locatelli F, Clyne N, Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355(20):2071-84
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339(9):584-90
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):495-505
   PubMed Web of Science ®Google Scholar
• Shuaib A, Lees KR, Lyden P, NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-71
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
   PubMed Web of Science ®Google Scholar
• Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator. A Science Advisory From the American Heart Association/American Stroke Association. Stroke 2009 May 28
   Google Scholar
• NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
   PubMed Web of Science ®Google Scholar
• Zechariah A, Elali A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010;41(5):1008-12
   PubMed Web of Science ®Google Scholar
• Jia L, Chopp M, Zhang L, Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke 2010; doi: 10.1161/STROKEAHA.110.586198
   Google Scholar
• CEPO. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00870844. Clinical Trial Design 2010
   Google Scholar